Science News
from research organizations

Antibiotic used on drug-eluting stents may lead to advances in heart disease and cancer treatment

Date:
April 15, 2010
Source:
Louisiana State University Health Sciences Center
Summary:
Researchers have identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries regulates cell movement, which is critical to wound healing and the progression of diseases like cancer.
Share:
       
FULL STORY

Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

The study is published in the April 16th issue of the Journal of Biological Chemistry.

The antibiotic, rapamycin, is used on drug-eluting stents implanted during angioplasty because it is effective in preventing restenosis (re-narrowing or reclosure) of arteries. However, rapamycin can also prevent tissue from growing over and covering the metal stents, a critical part of the artery's healing after angioplasty. Without this protective covering, blood clots can develop many months later, called late stent thrombosis. These clots can lead to a heart attack.

"Late stent thrombosis has emerged as a major factor diminishing the benefits of drug-eluting stents, highlighting the need for a better understanding of the antimigratory mechanism of rapamycin and its analogs," notes Dr. Woods.

Through a series of experiments, the researchers found that by silencing a protein made by cells exposed to mTOR inhibitors, a class of drugs including rapamycin, they could block rapamycin's inhibitory effect on cell migration.

"We identified specific changes in proteins that a class of drugs, called mTOR inhibitors, uses to block cell movement," said Dr. Woods. "This knowledge will help us to better design strategies to help arteries heal following angioplasty or to prevent tumor growth."

Studies like this one often have application beyond the original research question because they identify basic mechanisms involved in many biologic processes. Cell migration in cancer is not only important in tumor growth, but also in the spread of cancer to other sites in the body.

Heart disease is the leading cause of death in the United States. Coronary heart disease is the most common type of heart disease. According to the American Heart Association, in 2006, an estimated 1.3 million angioplasty procedures were performed. It has been estimated that about 60% of angioplasty procedures performed now are performed with drug-eluting stents.

Cancer is the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.

The research team also included Stephanie Moss and Daniel Lightell, Jr. at Ochsner Clinic Foundation, and Steven O. Marx, MD, and Andrew R. Marks, MD from Columbia University College of Physicians and Surgeons..

This research was funded by a COBRE grant from the National Institutes of Health's National Center for Research Resources to LSU Health Sciences Center New Orleans Department of Pharmacology and grants from the Greater Southeast Affiliate of the American Heart Association to Ochsner Clinic Foundation.


Story Source:

The above story is based on materials provided by Louisiana State University Health Sciences Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. C. Moss, D. J. Lightell, S. O. Marx, A. R. Marks, T. C. Woods. Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1. Journal of Biological Chemistry, 2010; 285 (16): 11991 DOI: 10.1074/jbc.M109.066621

Cite This Page:

Louisiana State University Health Sciences Center. "Antibiotic used on drug-eluting stents may lead to advances in heart disease and cancer treatment." ScienceDaily. ScienceDaily, 15 April 2010. <www.sciencedaily.com/releases/2010/04/100414122641.htm>.
Louisiana State University Health Sciences Center. (2010, April 15). Antibiotic used on drug-eluting stents may lead to advances in heart disease and cancer treatment. ScienceDaily. Retrieved May 30, 2015 from www.sciencedaily.com/releases/2010/04/100414122641.htm
Louisiana State University Health Sciences Center. "Antibiotic used on drug-eluting stents may lead to advances in heart disease and cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2010/04/100414122641.htm (accessed May 30, 2015).

Share This Page: